Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinoma
Referencias
Additional references
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. Journal of Clinical Oncology 2009;27(9):1485‐91. [DOI: 10.1200/JCO.2008.20.7753; PUBMED: PMC2668555]
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088‐101. [DOI: 10.2307/2533446; PUBMED: 7786990]
Breedis C, Young G. The blood supply of neoplasms in the liver. American Journal of Pathology 1954;30(5):969‐85. [PUBMED: PMC1942491]
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61:763‐9. [PUBMED: 18411040]
Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98. [PUBMED: 18824466]
Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208‐36. [DOI: 10.1002/hep.20933; PUBMED: 16250051]
Calvet X, Bruix J, Brú C, Ginés P, Vilana R, Solé M, et al. Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. Journal of Hepatology 1990;10(3):311‐7. [DOI: 10.1016/0168‐8278(90)90138‐H; PUBMED: 2164055 ]
Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver International 2010;30(2):166‐74. [DOI: 10.1111/j.1478‐3231.2009.02166.x; PUBMED: 19912531]
Chuang VP, Wallace S. Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 1981;140(1):51‐8. [PUBMED: 7244243]
Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 11 June 2013).
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El‐Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population‐based study. Gastroenterology 2004;127(5):1372‐80. [DOI: 10.1053/j.gastro.2004.07.020; PUBMED: 15521006]
Di Bisceglie AM, Befeler AS. Tumors and cysts of the liver. In: Feldman M, Friedman LS, Brandt LJ editor(s). Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th Edition. St. Louis: Saunders, 2010:1569‐92.
Doyon D, Mouzon A, Jourde AM, Regensberg C, Frileux C. Hepatic, arterial embolization in patients with malignant liver tumours. Annales de Radiologie 1974;17(6):593‐603. [PUBMED: 4142843]
Egger M, Smith G‐D, Schneider M, Minder C. Bias in meta‐analysis detected by a simple graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. [DOI: 10.1136/bmj.315.7109.629; PUBMED: 9310563]
Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als‐Nielsen B, Colli A, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 5. Art. No.: LIVER.
Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938‐46. [DOI: 10.1002/cncr.24982; PUBMED: 20166205]
Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta‐regression. Statistics in Medicine 2004;23:1663‐82. [DOI: 10.1002/sim.1752; PUBMED: 15160401]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.) 1999;319:670‐4. [DOI: 10.1136/bmj.319.7211.670; PUBMED: 10480822]
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of Hepatology 2003;38(2):200‐7. [DOI: 10.1016/S0168‐8278(02)00360‐4; PUBMED: 12547409]
Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994;20(2):295‐301. [DOI: 10.1002/hep.1840200205; PUBMED: 8045490]
Kakizaki S, Takagi H, Katakai K, Kanda D, Kosone T, Kojima A, et al. The natural history of untreated hepatocellular carcinoma. International Journal of Clinical Oncology 1997;3(5):299‐303. [DOI: 10.1007/BF02628050]
Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Annals of Surgery 2009;249(4):617‐23. [DOI: 10.1097/SLA.0b013e31819ed22f; PUBMED: 19300227]
Kim JH, Yoon HK, Ko GY, Gwon D, Jang CS, Song HY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010;255:270‐7. [DOI: 10.1148/radiol.09091076]
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9.
Lau WY. Primary liver tumors. Seminars in Surgical Oncology 2000;19:135‐44. [DOI: 10.1002/1098‐2388(200009)19:2<135::AID‐SSU6>3.0.CO;2‐A; PUBMED: 11126378]
Lau WY, Lai EH, Lau SH. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary & Pancreatic Diseases International 2009;8(2):124‐33. [PUBMED: 19357024]
Lee KH, Sung KB, Lee DY, Park SJ, Kim KW, Yu JS. Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and hemodynamic considerations in the hepatic artery and portal vein. Radiographics 2002;22(5):1077‐91. [PUBMED: 12235337]
Li JQ, Zhang YQ, Zhang WZ, Yuan YF, Li GH. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. Journal of Cancer Research and Clinical Oncology 1995;121(6):364‐6. [DOI: 10.1007/BF01225689; PUBMED: 7541051]
Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Qian BY, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomised study with 131 cases. Digestive Surgery 2006;23(4):235‐40. [PUBMED: 16943671]
Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug‐eluting chemoembolization?. Cardiovascular and Interventional Radiology 2011;34(1):37‐49. [DOI: 10.1007/s00270‐010‐0012‐y; PUBMED: 21069333]
Lin SC, Shih SC, Kao CR, Chou SY. Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis. World Journal of Gastroenterology 2003;9(6):1208‐11. [PUBMED: 12800225]
Lu X, Zhao HT, Mao YL, Sang XT, Xu YY, Du SD, et al. Early recurrence after the resection of hepatocellular carcinoma. Acta Academiae Medicinae Sinicae 2008;30(4):415‐20. [PUBMED: 18795612]
Lui HF. Screening for hepatocellular carcinoma. International Journal of Hepatology 2011;2011:363151. [DOI: 10.4061/2011/363151]
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treatment Reviews 2006;32:594‐606. [DOI: 10.1016/j.ctrv.2006.08.002; PUBMED: 17045407]
Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. [DOI: 10.1192/bjp.176.3.249; PUBMED: 10755072]
Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot FR, et al. Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2003;17(10):1247‐61. [PUBMED: 12755838]
McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clinics in Liver Disease 2011;15(2):223‐42. [DOI: 10.1016/j.cld.2011.03.006; PUBMED: 21689610]
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13.
Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Seminars in Liver Disease 1986;6(3):259‐66. [DOI: 10.1055/s‐2008‐1040608; PUBMED: 3022387]
Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Annals of Surgery 2009;249(5):799‐805. [DOI: 10.1097/SLA.0b013e3181a38eb5; PUBMED: 19387322]
Okada S. Cancer chemoprevention as adjuvant therapy for hepatocellular carcinoma. Japanese Journal of Clinical Oncology 2001;31(8):357‐8. [DOI: 10.1093/jjco/hye081; PUBMED: 11574626]
Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56(4):918‐28. [DOI: 10.1002/1097‐0142(19850815)56:4<918::AID‐CNCR2820560437>3.0.CO;2‐E; PUBMED: 2990661]
Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2]
Otto G, Heuschen U, Hofmann WJ, Krumm G, Hinz U, Herfarth C. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Annals of Surgery 1998;227(3):424‐32. [PUBMED: 9527066]
Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumour thrombus. American Journal of Surgery 2009;198(3):313‐8. [PUBMED: 19285298]
Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Annals of Surgery 2000;232:10‐24. [PUBMED: PMC1421103]
Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology 2011;54(3):757‐9. [DOI: 10.1002/hep.24569; PUBMED: 21793027]
Pua U, Wong DE. Transarterial embolisation of spontaneous adrenal pheochromocytoma rupture using polyvinyl alcohol particles. Singapore Medical Journal 2008;49(5):e126‐a130. [PUBMED: 18465036]
Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World Journal of Gastroenterology 2009;15(26):3210‐6. [DOI: 10.3748/wjg.15.3210; PUBMED: 19598295 ]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603.
Sakamoto I, Aso N, Nagaoki K, Matsuoka Y, Uetani M, Ashizawa K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998;18(3):605‐19. [PUBMED: 9599386]
Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. The Oncologist 2010;15(Suppl 4):14‐22. [DOI: 10.1634/theoncologist.2010‐S4‐14; PUBMED: 21115577]
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429‐38. [PUBMED: 22945832]
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1‐82. [PUBMED: 22989478]
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [PUBMED: 7823387]
Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA: Cancer Journal for Clinicians 2013;63(1):11‐30. [DOI: 10.3322/caac.21166]
Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses. International Journal of Epidemiology 2009;38(1):276‐86. [PUBMED: 18824467]
Thorlund K, Anema A, Mills E. Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology 2010;2:57‐66. [PUBMED: 20865104]
Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 11 June 2013).
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61:64‐75. [DOI: 10.1016/j.jclinepi.2007.03.013; PUBMED: 18083463]
Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology 2009;9:86. [DOI: 10.1186/1471‐2288‐9‐86; PUBMED: 20042080]
World Health Organization. Cause of death 2008 summary tables. www.who.int/gho/mortality_burden_disease/ (accessed 27 June 2013).
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5.
Yeh CN, Lee WC, Chen MF, Tsay PK. Predictors of long‐term disease‐free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Annals of Surgical Oncology 2003;10(8):916‐21. [DOI: 10.1245/ASO.2003.09.012; PUBMED: 14527911]
Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated non‐surgical hepatocellular carcinoma. American Journal of Gastroenterology 2005;100(9):1995‐2004. [DOI: 10.1111/j.1572‐0241.2005.00229.x; PUBMED: 16128944]
Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta‐analysis of randomised trials. Anticancer Drugs 2010;21(3):326‐32. [PUBMED: 20016366 ]
Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, et al. A randomised controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2009;135(10):1437‐45. [PUBMED: 19408012]
Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta‐analysis. Hepatology Research 2010;40(10):943‐54. [DOI: 10.1111/j.1872‐034X.2010.00710.x; PUBMED: 20887328]
Zhou L, Liu C, Meng FD, Qu K, Tian F, Tai MH, et al. Long‐term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pacific Journal of Cancer Prevention 2012;13(2):483‐6. [DOI: 10.7314/APJCP.2012.13.2.483; PUBMED: 22524811]
